Bevacizumab (Avastin)
From Glioblastoma Treatments
| Property | Information |
|---|---|
| Drug Name | Bevacizumab (Avastin) |
| Overview | |
| FDA Approval | Yes, for recurrent glioblastoma |
| Used for | Glioblastoma |
| Clinical Trial Phase | Phase III |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Hypertension, proteinuria, and hemorrhage |
| OS without | Not specified |
| OS with | AVAglio trial: 16.8 months; RTOG trial: 15.7 months |
| PFS without | Not specified |
| PFS with | Not specified |
| Usefulness Rating | 4 |
| Usefulness Explanation | Not specified |
| Toxicity Level | Not specified |
| Toxicity Explanation | Not specified |
Notes: Avastin improves PFS when used initially, but no significant benefit for overall survival compared to Avastin given at recurrence.
From Ben Williams Book: Not specified
Loading comments...
